Eisai Co. and its subsidiaries are engaged in the manufacture and sale of pharmaceuticals, consumer health care products, diagnostic products, chemicals and food additives, and animal health products. Co.'s products include antiallergy agent, osteoporosis treatment, gastritis/gastric ulcer... More
Wednesday, Mar 58:46 AM
Wednesday, Mar 58:46 AM| Comment!
- Biogen Idec (BIIB) has purchased the rights to two experimental treatments for Alzheimer's disease from Japan's Eisai.
- Biogen will pay Eisai an unspecified amount upfront and milestones. If the drugs, called E2609 and BAN2401, are commercialized, the companies will share the profits.
- Eisai (ESALF) will lead the development of the therapies and pursue regulatory authorization, although both companies will co-promote the drugs in the U.S., Europe and other markets.
- "Eisai's candidates have demonstrated compelling early data and complement our Alzheimer's disease research while extending our pipeline in this critical area," says Biogen CEO George Scangos.
Monday, Feb 37:44 AM
Thursday, Nov 72013, 4:29 PM
Thursday, Nov 72013, 4:29 PM| 7 Comments
- Arena Pharmaceuticals (ARNA) expands its Belviq marketing agreement with Eisai (ESALF).
- Eisai now has commercialization rights "for all countries worldwide, except for South Korea, Taiwan, Australia, Israel, and New Zealand."
- ARNA gets $60M upfront and is eligible for up to $176.5M in milestone payments and up to $1.56B in one-time purchase price adjustment payments.
- ARNA will still recognize 31.5% of North American sales and 30.75% of sales in South America. Rates under new agreement: Europe, China, and Japan, 27.5%; 30.75% elsewhere. Rates may rise as high as 35% in Europe, China, and Asia on sales over $500M.
- The companies also say they plan to "investigate the potential of Belviq in new areas, such as smoking cessation, a once-daily formulation, a fixed-dose combination with phentermine, as well as explore Belviq's impact on diabetes and cardiovascular outcomes." (PR)
- See also: ARNA Q3 results
Friday, Nov 12013, 8:03 AM
Wednesday, Oct 162013, 9:08 AM
Wednesday, Oct 162013, 9:08 AM| 4 Comments
- "Based on the ratio of NRx/TRx, refill rates appear to be low," Needham's Alan Carr says, referring to Arena's (ARNA) Belviq.
- The shares rallied sharply Tuesday, after marketing partner Eisai (ESALF.PK) said it will double its sales force for the weight-loss drug.
- Nevertheless, Carr says "Belviq patient awareness [is] low." The analyst also calls single-agent efficacy "modest."
- Hold rating reiterated.
- ARNA +1.3% premarket.
Tuesday, Oct 152013, 9:31 AM
Tuesday, Oct 152013, 9:31 AM| 1 Comment
- Arena Pharmaceuticals (ARNA +5%) says Belviq marketing partner Eisai (ESALF.PK) is set to double the size of its sales force for the weight-loss drug by December.
- The move will "will enable Eisai to reach approximately 65K physicians in the U.S.," ARNA notes.
- Eisai says the expansion "demonstrates the success ... gained in discussing the [drug's] potential value within the payor community, and the subsequent agreements ... reached with many ... payor partners." (PR)
- Worth noting: In a bearish note late last month, Credit Suisse predicted Eisai would need to hire additional reps in order for the companies to hit the bank's (lowered) Belviq estimates.
Tuesday, Oct 12013, 1:12 PM
Tuesday, Oct 12013, 1:12 PM| 11 Comments
- Piper Jaffray cuts its price target on Arena Pharmaceuticals (ARNA -6.8%) to $10 from $11.50, which was exactly what the stock did not need on the heels of Monday's Credit Suisse bear call.
- According to market chatter, Edward Tenthoff has cut Q3 Belviq sales estimates to $1/4M versus $4/14M previously.
Monday, Sep 302013, 10:11 AM
Monday, Sep 302013, 10:11 AM| 3 Comments
- A downbeat note out of Credit Suisse hits shares of Arena Pharmaceuticals (ARNA -6.6%) hard in early trading.
- CS slashes Belviq estimates for Q4, FY14, and FY15 to $12M (from $36M), $157M, and $325M, noting that although "these are substantial cuts ... getting to [the] new numbers will still require exponential growth [and] will require Eisai (ESALF.PK) to hire additional reps."
- Other (decisively bearish) takeaways: Profitability is now forecast for 2017 (versus 2016 previously), "slower ramp results in lower royalties and also defers the timing of milestone payments," the company "may need to do another round of financing next year."
- Price target cut to $4 from $5.
- Also lower: VVUS
Monday, Sep 162013, 8:34 AM
Monday, Sep 162013, 8:34 AM| Comment!
- Arena (ARNA) updates investors on partner Eisai's (ESALF.PK) Belviq marketing initiatives.
- ARNA says full-page ads will begin running this month in The Oprah Magazine, so the weight-loss drug has got that going for it.
- Also mentioned is Eisai's program to provide "support and savings" for Belviq patients. (PR)
- For more on Belviq's advertising campaign see SA contributor Spencer Osborne's latest article here
- Also: Belviq weekly TRx
- ARNA +3% premarket. Competitor VVUS +2.4% premarket
Friday, Aug 302013, 11:39 AM
Friday, Aug 302013, 11:39 AM| 1 Comment
- Astex Pharmaceuticals (ASTX -4.1%) is notably weak today after running up ~25% on Wednesday following topline data from a Phase 2 trial of SGI-110.
- Not helping the stock's cause is an article from theStreet's Adam Feuerstein who takes issue with RBC analyst Michael Yee's bullish thesis.
- "Concluding that SGI-110 is better than Dacogen [another ASTX product which is licensed to Eisai (ESALF.PK)] based on an interim look at just 17 patients is silly," Feuerstein says, adding that the observed 53% response rate in the cohort of elderly patients with treatment-naive AML "will not hold up once the cohort ... reaches full enrollment."
- Ultimately, Feuerstein thinks it's "premature to say much of anything about SGI-110's activity in AML relative to Dacogen based on the paltry and incomplete data released ... on Wednesday."
- For the record, the company says it released interim results because "the data was material and ASH just cleared [the company] for top-line data release without violating the embargo."
Wednesday, Aug 282013, 9:05 AM
Wednesday, Aug 282013, 9:05 AM| 1 Comment
- RBC's Michael Yee reiterates an Outperform rating on Astex Pharmaceuticals (ASTX) following topline data from an ongoing trial of SGI-110.
- Yee thinks the shares have significant room to run even after the 18% gain the stock has posted premarket — price target is $9.
- RBC likes SGI-110 compared to Eisai's (ESALF.PK) Dacogen (indicated for Myelodysplastic syndrome).
Thursday, Aug 12013, 8:41 AM
Thursday, Aug 12013, 8:41 AM| Comment!
- Arena Pharmaceuticals (ARNA) and Belviq partner Eisai (ESALY.PK) report quarterly results, giving investors a look at Belviq sales figures.
- Belviq sales come in at $4.13M. ARNA recognizes $1.3M of the net product sales. Scripts filled between June 11 and July 19: 12,500.
- ARNA on the call: "Too early to provide sales guidance." (webcast)
- ARNA received $65M in milestone payments for the quarter. (PR)
- ARNA +2.5% premarket. Eisai PR.
Friday, Jun 72013, 8:47 AM
Wednesday, Jun 52013, 2:47 PM
Monday, Mar 42013, 8:15 AMMore on Arena Pharmaceutical (ARNA -1.7%) Q4: In addition to revenues from Belviq sales, Arena expects $66.5M in milestone payments from marketing and distribution partner Eisai in 2013, $6M from amortization of upfront payments, and $3M from manufacturing services from Siegfried. Arena also expects R&D costs of $70-78M and G&A expenses of $28-34M. (PR) |Monday, Mar 42013, 8:15 AM| Comment!
Monday, Dec 242012, 7:27 AMThe marketing partner (Eisai ESALY.PK) for Arena's (ARNA) obesity-fighting Belviq has petitioned the DEA to expedite its approval process. If granted (this sort of request is rarely denied), this could have the drug in pharmacies on February 7, writes Joe Dedvukaj. Combined with what looks to be imminent EU approval, Street analysts will find themselves needing to catch up to lofty sales figures. |Monday, Dec 242012, 7:27 AM| 3 Comments
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.